Trials / Completed
CompletedNCT01124669
Biomarkers in Blood Samples From Patients With Refractory Non-Small Cell Lung Cancer Previously Treated With Sorafenib Tosylate
BRAF, KRAS and EGFR Mutation Detection in Non-Small Cell Lung Cancer Patients Treated With Sorafenib Monotherapy
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 80 (actual)
- Sponsor
- ECOG-ACRIN Cancer Research Group · Network
- Sex
- All
- Age
- 18 Years – 120 Years
- Healthy volunteers
- Not accepted
Summary
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This research study is studying biomarkers in blood samples from patients with refractory non-small cell lung cancer previously treated with sorafenib tosylate.
Detailed description
OBJECTIVES: * To determine the mutation rates of BRAF, KRAS, and EGFR in patients with non-small cell lung cancer treated with sorafenib tosylate on protocol ECOG-2501. * To determine the association between BRAF, KRAS, or EGFR mutation status and clinical benefits in patients treated with this regimen. OUTLINE: This is a multicenter study. DNA is isolated from archived plasma samples and analyzed for BRAF, KRAS, and EGFR mutations.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| GENETIC | DNA analysis | |
| GENETIC | mutation analysis | |
| OTHER | laboratory biomarker analysis |
Timeline
- Start date
- 2010-06-13
- Primary completion
- 2010-07-13
- Completion
- 2010-07-13
- First posted
- 2010-05-17
- Last updated
- 2017-05-17
Source: ClinicalTrials.gov record NCT01124669. Inclusion in this directory is not an endorsement.